Oracle Corporation (ORCL) Stock: Rises as AstraZeneca AI Partnership Targets Clinical Trials

TLDR Oracle stock gains 1.20% as AstraZeneca AI agreement puts healthcare in focus. Non-binding Oracle-AstraZeneca deal targets faster clinical trial recruitment. AI tools could help clinicians identify eligible patients for clinical trials. Initial plans span cancer, heart, kidney, respiratory, and rare disease research. Partners plan shared oversight and outcome measures before any broader rollout. Oracle [...]

The post Oracle Corporation (ORCL) Stock: Rises as AstraZeneca AI Partnership Targets Clinical Trials appeared first on Blockonomi.